http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005063695-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45f4b6f0a05df09f009ac8ea7413e8d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b9d212083c297d5c75d3b97ac90a50f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2ec6e2d02ee66deb082ec9236c13fa2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-41 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-41 |
| filingDate | 2003-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b6889b81c832e087abaa73578f4d3e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d661780b85c175ef5e465949f7dfaf8 |
| publicationDate | 2005-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005063695-A1 |
| titleOfInvention | Novel crystalline forms of entacapone, and production thereof |
| abstract | Disclosed are two novel crystalline forms of entacapone, form C and form D, which represent peripheral and selective COMT inhibitors that can be used for the treatment of Parkinson's disease in combination with levodopa and a decarboxylase inhibitor. Form C is produced by crystallizing entacapone from a mixture of at least one aromatic and at least one aliphatic hydrocarbon. Form D is produced by a) dissolving entacapone in a water-miscible solvent and introducing said solution into water or a mixed aqueous system, or b) dissolving entacapone in a polar aprotic or alcoholic solvent and adding said solution to an aliphatic hydrocarbon which can be mixed with said solvent and in which entacapone is insoluble, or c) crystallizing entacapone in a non-acidic solvent or a solvent mixture containing at least one non-acidic component in the presence of a strong acid, the entacapone being usable as a raw product or, in variant c), as the Knoevenagel condensation product of 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyano-acetamide, which is used in situ. Also disclosed are improvements of said Knoevenagel condensation regarding the catalyst used and regarding the production of the two components thereof, 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyano-acetamide. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008098960-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008062432-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007113845-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7750177-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105061259-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112624941-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2306587-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008058992-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1935873-A1 |
| priorityDate | 2003-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.